Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Total Debt (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Total Debt for 15 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Debt fell 43.04% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 43.04%, and an annual FY2024 reading of $2.5 million, down 3.71% over the prior year.
  • Total Debt was $2.0 million for Q3 2025 at BioRestorative Therapies, down from $2.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $14.2 million in Q1 2022 and bottomed at $250000.0 in Q1 2021.
  • Average Total Debt over 5 years is $4.3 million, with a median of $3.2 million recorded in 2025.
  • The sharpest move saw Total Debt crashed 94.29% in 2021, then surged 5582.17% in 2022.
  • Year by year, Total Debt stood at $308970.0 in 2021, then soared by 1693.62% to $5.5 million in 2022, then plummeted by 52.76% to $2.6 million in 2023, then fell by 3.71% to $2.5 million in 2024, then fell by 21.92% to $2.0 million in 2025.
  • Business Quant data shows Total Debt for BRTX at $2.0 million in Q3 2025, $2.6 million in Q2 2025, and $3.2 million in Q1 2025.